Wawrzynek A.,Med University |
Dobiala J.,Neuropsych Hospital |
Wender M.,Neurological Unit |
Kozubski W.,Med University |
And 2 more authors.
Neurologia i Neurochirurgia Polska | Year: 2014
TNFα, a significant immune mediator, may contribute to the initiation and progression of the ischemic stroke. Genetics of TNFα molecule may have an important role in the risk of ischemic stroke. The most interesting aspects of the G-308A polymorphism remain unexplained; there are many discrepancies between the results. Differences in the ethnicity of the studied cohorts may be taken as one of the possibility. Our study material consisted of 101 patients with ischemic stroke, including 30% classified as lacunar stroke. The diagnosis was based on the presence of rapidly developing neurological signs lasting longer then 24 h and confirmed by neuroimaging matter. All patients were of Polish Caucasian origin. Randomly selected 100 individuals without any sign of the vascular disease of central nervous system were taken as the control material. The frequency of polymorphism G-308A in TNFα gene was determined as described by Rubattu et al. . The genotype distribution in our material was similar and statistically insignificant between patients and controls. The heterozygotic G/A genotype was detected in 9% of patients and in 15% of control materials, homozygotic A/A was found in 5% of patients and only in one of control and G/G in 87% of patients and in 84% of control individuals. Our results are negative with respect to the impact of 308 TNFα polymorphism on the risk of ischemic stroke in Caucasians living in Poland. © 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
PubMed | Med University
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2016
5072 Background: Pegylated liposomal doxorubicin ( PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions were reported as being the dose-limiting toxicity and have an impact on patients quality of life (QoL). The objective of this study was to optimize the toxicity profile by choosing a biweekly schedule of PLD according to the experience in patients with AIDS-related Kaposi sarcoma. A specific symptom check list was used to investigate QoL. Secondary objective of this study was to evaluate the response rates of this new regimen.We performed a multi-institutional phase-II study to analyze the toxicity profile of PLD (20mg/mA total of 65 pts were recruited (10/2001-11/2003). 419 courses (median: 6, range: 1-22) were evaluable. Median age was 59 (35-80). Only 12 of the pts were in second-line, most of the pts were in third- or fourth-line. Nine pts were in fifth-line and one patient had 6 different prior regimens. Overall, the treatment was well tolerated. 24 pts developed skin toxicities: 15 pts with grade I, 5 with grade II and only 4 pts with grade III. These side effects occurred after a median of 6 courses. Heamatologic toxicity profile was favourable: no thrombocytopenia grade III/IV was observed. Only 3.2% episodes of lymphocytopenia grade III and 0.7% of grade IV occurred without clinical sequelae. Clinical response were evaluable by CA-125-monitoring and radiologic measurements. One patient developed a partial response, 24 ts developed a progressive disease after seven cycles (median) of treatment (range: 5-18).Despite the heavily pretreatment of the pts the results suggest that this new schedule seems to be an effective and well tolerated regimen, showing a low incidence of toxic skin reactions. The superiority over the conventional schedule must be clarified by a randomised trial. Supported by ESSEX Pharma Germany. No significant financial relationships to disclose.